EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Surveillance of adverse events following immunisation in Australia annual report, 2022

Yuanfei Anny Huang, Claire Larter, Megan Hickie, Megan O'Moore, Belinda Jones, Lucy Deng, Sophie Russell, Elspeth Kay, Kristine Macartney, Nicholas Wood

Communicable Diseases Intelligence · 2025

DOI: 10.33321/cdi.2025.49.043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Yuanfei Anny Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Immunisation Research and Surveillance, Locked Bag 4001, Westmead NSW 2145, Sydney, Australia. yuanfei.huang@health.nsw.gov.au. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, COVID-19, Vaccination, COVID-19 Vaccines. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This report summarises Australia’s spontaneous surveillance data for non-COVID-19 vaccine adverse events following immunisation (AEFI) for 2022, reported to the Therapeutic Goods Administration (TGA). National spontaneous (passive) surveillance data for coronavirus disease 2019 (COVID-19) vaccine AEFI reported to the TGA are analysed and discussed in a separate companion publication. There were 3,642 AEFI reports for non-COVID-19 vaccines administered in 2022, representing an annual AEFI reporting rate of 14.0 per 100,000 population, compared with 13.4 per 100,000 population in 2021. This very small increase in the AEFI reporting rate in 2022 could potentially be related to the combination of several factors: a gradual return to pre-pandemic AEFI reporting patterns; new vaccination programs in response to outbreaks of emergent vaccine preventable diseases (Japanese encephalitis and mpox); and a change in the reporting activities of pharmaceutical sponsors. AEFI reporting rates for individual vaccines in 2022 were similar to 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsCOVID-19VaccinationCOVID-19 VaccinesImmunizationHumansAustraliaChildSARS-CoV-2AdolescentAdultMiddle AgedChild, PreschoolInfantFemaleMaleYoung AdultAged

Stichwörter der Autor:innen

AEFIadverse eventsimmunisationsurveillancevaccinevaccines

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • National Centre for Immunisation Research and Surveillance, Locked Bag 4001, Westmead NSW 2145, Sydney, Australia. yuanfei.huang@health.nsw.gov.au.
  • Pharmacovigilance Branch, Therapeutic Goods Administration, Department of Health, Disability and Ageing, Canberra, Australia.
  • National Centre for Immunisation Research and Surveillance, The University of Sydney and The Children's Hospital at Westmead, Sydney, Australia.

Zitieren

APA

Huang, Y. A., Larter, C., Hickie, M., O'Moore, M., Jones, B., Deng, L., Russell, S., Kay, E., Macartney, K., & Wood, N. (2025). Surveillance of adverse events following immunisation in Australia annual report, 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.043

Vancouver

Huang YA, Larter C, Hickie M, O'Moore M, Jones B, Deng L, et al. Surveillance of adverse events following immunisation in Australia annual report, 2022. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.043

BibTeX
@article{Huang2025,
  author = {Huang, Yuanfei Anny and Larter, Claire and Hickie, Megan and O'Moore, Megan and Jones, Belinda and Deng, Lucy and Russell, Sophie and Kay, Elspeth and Macartney, Kristine and Wood, Nicholas},
  title = {Surveillance of adverse events following immunisation in Australia annual report, 2022},
  journal = {Communicable Diseases Intelligence},
  year = {2025},
  doi = {10.33321/cdi.2025.49.043}
}
Kostenlos starten →